Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
Cited by
Impulse Control Disorders in Parkinson Disease: A Cross-Sectional Study of 3090 Patients
Weintraub, D., Koester, J., Potenza, M. N., Siderowf, A. D., Stacy, M., Voon, V., Whetteckey, J., Wunderlich, G. R., & Lang, A. E. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.65 · Cited by 1,487
Pathological Gambling Caused by Drugs Used to Treat Parkinson Disease
Dodd, M. L., Klos, K. J., Bower, J. H., Geda, Y. E., Josephs, K. A., & Ahlskog, J. E. (2005) · Archives of Neurology · doi:10.1001/archneur.62.9.noc50009 · Cited by 563
Cognitive-behavioral therapy for psychogenic nonepileptic seizures: A pilot RCT
Goldstein, L. H., Chalder, T., Chigwedere, C., Khondoker, M. R., Moriarty, J., Toone, B. K., & Mellers, J. D. C. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e39658 · Cited by 477
Bodi, N., Keri, S., Nagy, H., Moustafa, A., Myers, C. E., Daw, N., Dibo, G., Takats, A., Bereczki, D., & Gluck, M. A. (2009) · Brain · doi:10.1093/brain/awp094 · Cited by 363
Levodopa‐induced dyskinesia in Parkinson disease: Current and evolving concepts
Espay, A. J., Morgante, F., Merola, A., Fasano, A., Marsili, L., Fox, S. H., Bezard, E., Picconi, B., Calabresi, P., & Lang, A. E. (2018) · Annals of Neurology · doi:10.1002/ana.25364 · Cited by 340
Prospective prevalence of pathologic gambling and medication association in Parkinson disease
Voon, V., Hassan, K., Zurowski, M., Duff-Canning, S., de Souza, M., Fox, S., Lang, A. E., & Miyasaki, J. (2006) · Neurology · doi:10.1212/01.wnl.0000218206.20920.4d · Cited by 329
Reversal learning in Parkinson's disease depends on medication status and outcome valence
Cools, R., Altamirano, L., & D’Esposito, M. (2006) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2006.03.030 · Cited by 289
Klos, K. J., Bower, J. H., Josephs, K. A., Matsumoto, J. Y., & Ahlskog, J. E. (2005) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2005.06.005 · Cited by 283
Impulse Control and Related Disorders in Parkinson's Disease
Weintraub, D., & Claassen, D. O. (2017) · International Review of Neurobiology · doi:10.1016/bs.irn.2017.04.006 · Cited by 272
Initiation of pharmacological therapy in Parkinson's disease: when, why, and how
de Bie, R. M. A., Clarke, C. E., Espay, A. J., Fox, S. H., & Lang, A. E. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30036-3 · Cited by 200
Anxiety in Parkinson’s disease: A critical review of experimental and clinical studies
Prediger, R. D. S., Matheus, F. C., Schwarzbold, M. L., Lima, M. M. S., & Vital, M. A. B. F. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.039 · Cited by 190
Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome
Paulus, W., & Trenkwalder, C. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70576-2 · Cited by 181
Depression and impulse control disorders in Parkinson׳s disease: two sides of the same coin?
Vriend, C., Pattij, T., van der Werf, Y. D., Voorn, P., Booij, J., Rutten, S., Berendse, H. W., & van den Heuvel, O. A. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.11.001 · Cited by 106
Bari, A., & Robbins, T. W. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3141-6 · Cited by 105
“2012), a compound with D3 receptor affinity comparable to that of pramipexole (Gerlach et al. 2003) on error awareness, consistent with the present results.”
ResultBagetta, V., Sgobio, C., Pendolino, V., Del Papa, G., Tozzi, A., Ghiglieri, V., Giampà, C., Zianni, E., Gardoni, F., Calabresi, P., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.2664-12.2012 · Cited by 74
“Among the increasing number of D2-like receptor agonists, pramipexole is currently the most prescribed for PD treatment, showing a preferential affinity also for the DA-D3 receptor subtype (D3R) and lacking affinity for D1 and D5 receptors (Gerlach et al., 2003).”
BackgroundNakum, S., & Cavanna, A. E. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.02.017 · Cited by 70
Gibbs, S. E. B., & D’Esposito, M. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2005.11.055 · Cited by 49
5.4 Dopaminergic Modulation of Flexible Cognitive Control in Humans
Cools, R., & D’Esposito, M. (2009) · Dopamine Handbook · doi:10.1093/acprof:oso/9780195373035.003.0017 · Cited by 46
The Effect of Dopamine Agonists on Adaptive and Aberrant Salience in Parkinson's Disease
Nagy, H., Levy-Gigi, E., Somlai, Z., Takáts, A., Bereczki, D., & Kéri, S. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.278 · Cited by 42
Management of impulse control disorders in Parkinson's disease
Zhang, S., Dissanayaka, N. N., Dawson, A., O'Sullivan, J. D., Mosley, P., Hall, W., & Carter, A. (2016) · International Psychogeriatrics · doi:10.1017/s104161021600096x · Cited by 22
Metadata
- Authors
- Gerlach, M., Double, K., Arzberger, T., Leblhuber, F., Tatschner, T., & Riederer, P.
- Venue
- Journal of Neural Transmission
- Published
- 2003-10-01
- Volume
- 110
- Issue
- 10
- Pages
- 1119-1127
- ISSN
- 0300-9564 (ISSN-L)
- 1435-1463
- OpenAlex
- W2083323215
- Cited by
- 187
- References
- 1
- FWCI
- 6.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.